Usage of cookies

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our Privacy policy.

Close
Skip to content

Press Release

FlexiSeq Sport demonstrates superiority to a prescription pain killer for the treatment of muscle soreness

Pro Bono Bio plc welcomes today the publication of an independent study into the effects of FLEXISEQ Sport versus a prescription pain killer on muscle soreness and recovery after exercise.

Published in the Journal of Sports Sciences1, the investigation shows that FLEXISEQ Sport reduces muscle soreness faster than a prescription oral painkiller (ketoprofen 100mg, twice daily), avoiding the known problem of NSAID-delayed recovery.

During the study, healthy volunteers aged 18-55 repeatedly descended stairs for 40 minutes from an altitude of up to 400m to induce muscle soreness 12 hours later. Participants with measurable muscle soreness in the calves were then randomised to a number of treatment arms including oral ketoprofen 100mg and drug-free FLEXISEQ Sport, both received twice daily for 7 days after the onset of muscle soreness.

Over the 7 days after exercise, participants taking oral ketoprofen experienced over 20% more pain than those using FLEXISEQ Sport; in addition, those treated with FLEXISEQ Sport found their muscle soreness was completely cleared on average 12 hours faster than those using the oral drug.

Study author, Professor Egbert J. Seidel, Centre for Physical and Rehabilitation Medicine, Weimar said, “This study reinforces other published findings that the use of NSAIDs to treat muscle soreness actually delays recovery rather than improves it. It is a concern in sport that athletes often take large amounts of painkillers prior to during and after events to reduce muscle soreness and these findings suggest that FLEXISEQ Sport could serve as a superior alternative.”

Additional findings showed that a greater number of patients using FLEXISEQ Sport(90%)had a complete absence of pain by the end of the study than those treated with oral ketoprofen 100mg (75%).

Nick Baverstock, Director of Sports Marketing at Pro Bono Bio said, “The findings of this study reflect the great feedback we have received from professional sport. FLEXISEQ Sport consistently demonstrates effectiveness in an array of recovery-based applications for a wide-variety of physically demanding disciplines and its superiority over NSAIDs for muscle recovery is an additional benefit to the use of the product. Once again, FLEXISEQ Sport has been proven to be the superior alternative to drugs which are too often used in sport with little concern for the side effects.”

The study findings will be of interest to sportsmen and women as they suggest that FLEXISEQ Sport’s biolubricating mode of action may have a dual function, to assist the joints in resisting the stress and strain of physical exertion, but also to aid muscle recovery in a similar way to muscle-bound hyaluronic acid which is thought to ensure the smooth sliding motion between fascia and muscle bundles2. This physical mode of action is preferable to the side effects associated with the inappropriate use of NSAIDS that has become commonplace in many sports. FLEXISEQ Sport now provides a safer and more effective way of dealing with muscle soreness.

1http://www.ncbi.nlm.nih.gov/pubmed/25893979
2STECCO, Carla et al. Analysis of the presence of the hyaluronic acid inside the deep fasciae and in the muscles. Italian Journal of Anatomy and Embryology, [S.l.], p. 179, Nov. 2011. ISSN 2038-5129. Available at: <http://www.fupress.net/index.php/ijae/article/view/10258>. Date accessed: 10 Apr. 2015. doi:10.13128/IJAE-10258




About Ascension

Ascension Healthcare plc is a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapies for the treatment of haemophilia and osteoarthritis.

The Company has three products in clinical or pre-clinical development for the treatment of Haemophilia A and also a range of internationally marketed products for osteoarthritis sufferers.

For more information please visit: https://ascension.co.uk/

For further information please contact

Ascension Healthcare plc
Biresh Roy, Chief Executive Officer
+44 (0)20 7291 5400
[email protected]

Consilium Strategic Communications
(European Media and Investor Enquiries)
Lindsey Neville, Priscila Radu
+44 (0)20 3709 5700
[email protected]

Ascension Healthcare plc
Biresh Roy, Chief Executive Officer

[email protected]
+44 (0)20 7291 5400